A subcutaneous form of Herceptin demonstrated activity and pharmacokinetics comparable to intravenous delivery in breast cancer patients

0

Intravenous literature: Medpage Today report “A subcutaneous form of trastuzumab (Herceptin) demonstrated activity and pharmacokinetics comparable to intravenous delivery in breast cancer patients who received the agent prior to surgery, results of a randomized trial showed. Both formulations achieved pathologic complete response rates of 40% to 45% and similar serum trough concentrations, the two primary endpoints, as reported online in The Lancet Oncology.

The demonstration of noninferiority suggests the more convenient subcutaneous formulation offers a valid alternative to intravenous trastuzumab, said Gustavo Ismael, MD, Hospital Amaral Carvalho in Jaú, Brazil, and colleagues.”

Click here to view the full story.

Main page

Share.

Comments are closed.

Free Email Updates
Join 5.5K IVTEAM members. Subscribe now and be the first to receive all the latest free updates from IVTEAM!
100% Privacy. We don't spam.